Drugs / Flotetuzumab
Trials 8
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2020-12-06 | MacroGenics | Results MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting macrogenics.com ↗
In the open label study of flotetuzumab, 44 AML patients had disease classified as either PIF or ER6. |
| 2020-10-15 | MacroGenics | Results MacroGenics Announces Flotetuzumab Publication in Blood Advances macrogenics.com ↗
The same gene signature was shown to be associated with an increased probability of this subset of patients to respond to flotetuzumab. |
| 2020-09-22 | MacroGenics | Results MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood macrogenics.com ↗
The most common treatment-related adverse event (TRAE) was infusion-related reaction/cytokine release syndrome (IRR/CRS), the majority reported as grade 1-2. |
| 2020-06-03 | MacroGenics | Results MacroGenics Announces Publication in Science Translational Medicine Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid Leukemia macrogenics.com ↗
The data indicated that an inflammatory signature related to INF-γ gene expression was predictive of resistance to chemotherapy and potential response to flotetuzumab immunotherapy in patients with primary refractory or early relapsed AML. |
| 2020-04-27 | MacroGenics | Results MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting macrogenics.com ↗
The data suggests that TP53 mutations in AML associate with an immune-infiltrated tumor microenvironment (TME) characterized by high expression of IFN-γ signaling molecules and immune checkpoints. |
| 2019-12-09 | MacroGenics | Results MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting macrogenics.com ↗
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from a Phase 1/2 dose expansion study of flotetuzumab, an investigational, bispecific CD123 x CD3 DART® molecule in patients with primary induction failure and early relapsed acute myeloid leukemia (AML). |
| 2018-12-03 | MacroGenics | Results Phase 1 Expansion Cohort Oral Presentations for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, in Relapsed/Refractory Acute Myeloid Leukemia Presented at 60th ASH Annual Meeting macrogenics.com ↗
Flotetuzumab demonstrated 29.4% complete response rate in evaluable primary refractory AML patients |
All press releases naming this drug 15 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flotetuzumab | “This phase II trial studies how well flotetuzumab works in treating patients with CD123 positive blood cancer that has come back or does not respond to treatment.” NCT03739606 ↗ |
| Known as | MGD-006 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990038 ↗ |
| Known as | NSC#808294 | “A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia” NCT04158739 ↗ |
| Known as | RES-234 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990038 ↗ |
| Known as | S-80880 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990038 ↗ |
| Modality | Monoclonal antibody | “Immunotherapy with monoclonal antibodies, such as flotetuzumab, may help the body's immune system attack the cancer” NCT03739606 ↗ |
| Route | Intravenous | “Given IV” NCT03739606 ↗ |
| Target | IL3RA | “Interleukin-3 receptor subunit alpha binding agent” CHEMBL3990038 ↗ |